Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Evaluating sexual dysfunction in young women with breast cancer

Cynthia Villarreal-Garza • 13 Mar 2025
BCC 2025
Breast Cancer

Cynthia Villarreal-Garza, MD, DSc, TecSalud, Monterrey, Mexico, comments on the prevalence of sexual dysfunction in young women with breast cancer. In Mexico, approximately half of patients experience persistent sexual dysfunction after 5 years, emphasizing the need for active management to improve patient outcomes. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Cynthia Villarreal-Garza

Survivorship challenges in young patients with breast cancer
0:56
Survivorship challenges in young patients with breast cancer
Cynthia Villarreal-Garza • 13 Mar 2025
Unmet needs in younger patients with breast cancer
1:43
Unmet needs in younger patients with breast cancer
Cynthia Villarreal-Garza • 13 Mar 2025
Improving access to endocrine therapies in Mexico
1:00
Improving access to endocrine therapies in Mexico
Cynthia Villarreal-Garza • 25 Mar 2021
Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico
4:05
Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico
Cynthia Villarreal-Garza • 25 Mar 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals